Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AKCEA THERAPEUTICS, INC.AKCA · Entity 145982 | Chief Financial Officer | July 13, 2017 | July 14, 2017 |
| Artiva Biotherapeutics, Inc.ARTV · Entity 5404 | Director | September 10, 2026 | September 14, 2026 |
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | EVP, Finance & CFO | March 16, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AKCEA THERAPEUTICS, INC.
Report date July 13, 2017 · Filed July 14, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| No securities are beneficially owned.SEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2017-07-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Artiva Biotherapeutics, Inc.
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2036-09-09 | Direct | 16,250 |
Reported balance
After 2026-09-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-10 · Grant · Acquired 16,250 · Balance 16,250 F1: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.
IONIS PHARMACEUTICALS INC
Report date March 16, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,660 |
Ending reported balance
After 2026-03-17 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-03-16 · Exercise / conversion · Acquired 60,299 · Balance 193,180 Row 2 · 2026-03-16 · Exercise / conversion · Acquired 61,041 · Balance 254,221 Row 3 · 2026-03-16 · Exercise / conversion · Acquired 33,118 · Balance 287,339 Row 4 · 2026-03-16 · Exercise / conversion · Acquired 20,541 · Balance 307,880 Row 5 · 2026-03-16 · Sale · Disposed 205,608 · Balance 102,272 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 9, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.70 to $72.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Row 6 · 2026-03-16 · Sale · Disposed 9,440 · Balance 92,832 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 9, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.71 to $72.88 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Row 7 · 2026-03-17 · Sale · Disposed 10,172 · Balance 82,660 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 9, 2025. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.11 to $73.28 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.60 · Expires 2032-01-02 | Direct | 0 |
Reported balance
After 2026-03-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-03-16 · Exercise / conversion · Disposed 33,118 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.58 · Expires 2033-01-02 | Direct | 5,405 |
Reported balance
After 2026-03-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-03-16 · Exercise / conversion · Disposed 20,541 · Balance 5,405 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.78 · Expires 2028-01-03 | Direct | 0 |
Reported balance
After 2026-03-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-03-16 · Exercise / conversion · Disposed 61,041 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.89 · Expires 2027-01-01 | Direct | 0 |
Reported balance
After 2026-03-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-03-16 · Exercise / conversion · Disposed 60,299 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 9, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.70 to $72.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.71 to $72.88 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.11 to $73.28 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 25, 2019 Filed Nov 26, 2019 22:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000874015-19-000138 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 4,000 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents the date on which the options are fully exercisable pursuant to the vesting schedule of the grant. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 22:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 4,000 | $62.50 | $250,000.00 |
DisclosureSEC source: 0000874015-19-000138 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,055 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 22:40 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 4,000 | $10.82 | $43,280.00 |
DisclosureSEC source: 0000874015-19-000138 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000874015-19-000134 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,700 Underlying: Common Stock · 4,000 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents the date on which the options are fully exercisable pursuant to the vesting schedule of the grant. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 4,000 | $58.80 | $235,200.00 |
DisclosureSEC source: 0000874015-19-000134 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,055 F1 · kind: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 4,000 | $10.82 | $43,280.00 |
DisclosureSEC source: 0000874015-19-000134 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 00:45 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 105 | $45.70 | $4,798.97 |
DisclosureSEC source: 0000874015-19-000087 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,055 F1 · kind: Reporting 105 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2019. These 105 shares may not be sold until January 2, 2020. F1 · shares: Reporting 105 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2019. These 105 shares may not be sold until January 2, 2020. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 00:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 7,891 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000026 · edgar.xml · derivative · entry 4 HOUGEN ELIZABETH L · CIK 0001074773 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,463 Underlying: Common Stock · 7,891 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 00:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 22,131 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000026 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,131 Underlying: Common Stock · 22,131 shares Expires not disclosed F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 00:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Tax withholdingCommon Stock | 2,842 | $58.26 | $165,574.92 |
DisclosureSEC source: 0000874015-19-000026 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,823 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 00:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 7,891 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000026 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:44 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 49,800 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-19-000010 · edgar.xml · derivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,800 Underlying: Common Stock · 49,800 shares Expires 2026-01-01 F2 · derivative.exercise_date: Grant of 01/02/2019 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 01/02/2020. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 01/02/2019. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 00:44 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 127 | $36.45 | $4,628.90 |
DisclosureSEC source: 0000874015-19-000010 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,901 F1 · kind: Reporting shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019. F1 · shares: Reporting shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 22:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,063 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-18-000132 · edgar.xml · derivative · entry 6 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,063 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 22:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,063 | $52.05 | $107,379.15 |
DisclosureSEC source: 0000874015-18-000132 · edgar.xml · nonDerivative · entry 4 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,774 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 22:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,063 | $7.25 | $14,956.75 |
DisclosureSEC source: 0000874015-18-000132 · edgar.xml · nonDerivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 22:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-18-000132 · edgar.xml · derivative · entry 5 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,063 Underlying: Common Stock · 2,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 22:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,000 | $52.00 | $104,000.00 |
DisclosureSEC source: 0000874015-18-000132 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,774 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 22:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,000 | $7.25 | $14,500.00 |
DisclosureSEC source: 0000874015-18-000132 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 19:31 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 274 | $35.42 | $9,704.94 |
DisclosureSEC source: 0000874015-18-000093 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,774 F1 · kind: Reporting 274 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2018. These 274 shares may not be sold until January 2, 2019. F1 · shares: Reporting 274 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2018. These 274 shares may not be sold until January 2, 2019. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 02:46 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,724 | $51.76 | $140,994.24 |
DisclosureSEC source: 0000874015-18-000027 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.760 to $51.763, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:46 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 6,732 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000027 · edgar.xml · derivative · entry 4 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,217 Underlying: Common Stock · 6,732 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:46 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 12,137 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000027 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,137 Underlying: Common Stock · 12,137 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. F6 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F6 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2018 Filed Jan 18, 2018 02:46 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 6,732 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000027 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 01:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 54,619 | $0.00 Strike: $49.25 | $0.00 |
DisclosureSEC source: 0000874015-18-000006 · edgar.xml · derivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,619 Underlying: Common Stock · 54,619 shares Expires 2025-01-01 F2 · derivative.exercise_date: Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 13,655 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 01:49 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 100 | $42.76 | $4,275.50 |
DisclosureSEC source: 0000874015-18-000006 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,492 F1 · kind: Reporting 100 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 100 shares may not be sold until July 2, 2018. F1 · shares: Reporting 100 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 100 shares may not be sold until July 2, 2018. Read SEC document |
| December 15, 2017 Filed Dec 20, 2017 01:20 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000073 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2017 Filed Dec 20, 2017 01:20 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,000 | $52.55 | $262,750.00 |
DisclosureSEC source: 0000874015-17-000073 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,392 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.34 to $52.65, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| December 15, 2017 Filed Dec 20, 2017 01:20 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 5,000 | $10.29 | $51,450.00 |
DisclosureSEC source: 0000874015-17-000073 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000072 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 4,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 4,000 | $57.00 | $228,000.00 |
DisclosureSEC source: 0000874015-17-000072 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,392 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 4,000 | $10.29 | $41,160.00 |
DisclosureSEC source: 0000874015-17-000072 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| November 29, 2017 Filed Dec 2, 2017 00:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000071 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 6,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2017 Filed Dec 2, 2017 00:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 6,000 | $53.02 | $318,120.00 |
DisclosureSEC source: 0000874015-17-000071 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,392 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.75 to $53.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| November 29, 2017 Filed Dec 2, 2017 00:12 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 6,000 | $10.29 | $61,740.00 |
DisclosureSEC source: 0000874015-17-000071 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 22:57 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000068 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 7,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 22:57 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 7,000 | $54.35 | $380,450.00 |
DisclosureSEC source: 0000874015-17-000068 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,392 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/15. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/15. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.02 to $54.58, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 22:57 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 7,000 | $10.29 | $72,030.00 |
DisclosureSEC source: 0000874015-17-000068 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/15. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/15. Read SEC document |
| July 01, 2017 Filed Jul 3, 2017 21:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 104 | $40.66 | $4,228.17 |
DisclosureSEC source: 0000874015-17-000046 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,392 F1 · kind: Reporting 104 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 104 shares may not be sold until January 2, 2018. F1 · shares: Reporting 104 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2017. These 104 shares may not be sold until January 2, 2018. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 623 | $46.29 | $28,838.67 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · nonDerivative · entry 10 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,288 F8 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. F8 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 539 | $46.29 | $24,950.85 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · nonDerivative · entry 8 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,317 F6 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. F6 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 733 | $46.29 | $33,930.57 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · nonDerivative · entry 6 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,476 F4 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. F4 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 256 | $46.29 | $11,850.24 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · nonDerivative · entry 4 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,334 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2013. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2013. Read SEC document |
| January 17, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 122 | $46.29 | $5,647.75 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,937 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2013. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2013. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 1,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · derivative · entry 16 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,779 Underlying: Common Stock · 1,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F8 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 1,380 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · derivative · entry 15 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,758 Underlying: Common Stock · 1,380 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F6 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · derivative · entry 14 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 653 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · derivative · entry 13 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 653 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2013. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 312 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · derivative · entry 12 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2013. F11 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F11 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 7,537 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · derivative · entry 11 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,537 Underlying: Common Stock · 7,537 shares Expires not disclosed F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F10 · derivative.exercise_date: Grant 1/15/2017 to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2021. The RSU is vested as to 0 shares on January 15, 2017. F10 · derivative.expiration_date: Grant 1/15/2017 to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2021. The RSU is vested as to 0 shares on January 15, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.